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Abstract
Health has gained importance on the global agenda. It has become recognized in forums where it
was once not addressed. In this article three issues are considered: global health policy actors,
global health priorities and the means of addressing the identified health priorities. I argue that the
arenas for global health policy-making have shifted from the public spheres towards arenas that
include the transnational for-profit sector. Global health policy has become increasingly fragmented
and verticalized. Infectious diseases have gained ground as global health priorities, while non-
communicable diseases and the broader issues of health systems development have been neglected.
Approaches to tackling the health problems are increasingly influenced by trade and industrial
interests with the emphasis on technological solutions.
Global health policy actors
The major actors in global health policy are changing.
New actors are entering and old ones are losing power; the
overall change has seen a shift from global nation-based
health-policy-making structures towards more diversity
that puts emphasis on private sector actors. In the 1980s
and 1990s there was a shift in global health policy making
from the UN agencies towards financial institutions. This
shift has meant increasing attention being given to involv-
ing private actors in health policy [1-4]. Towards the end
of the 20th century the UN increasingly collaborated with
business, which subsequently increased the influence of
private interests in the UN system. [5-8]. This develop-
ment was partly due to the declining levels of develop-
ment assistance of the OECD (Organisation for Economic
Co-operation and Development) countries to the UN,
which became particularly acute in the 1990s [9], and
partly due to the fear that the UN would become margin-
alized if it did not increase its collaboration with the cor-
porate sector, which had gained power in overall policy-
making [10].
In the UN forums, civil society has become recognized as
an important body of actors in global policy-making, as
seen at the UN Conference for Environment and Develop-
ment in 1992, and at the International Conference on
Population and Development in 1994, where women's
organisations were instrumental in shaping the Pro-
gramme of Action. Regarding health matters, the not-for-
profit sectors of the civil society have played an important
role for much longer, most notably in the debates con-
cerning essential drugs, breast milk substitutes, and wean-
ing foods in the 1970s and 1980s. [11]. More recently the
public health NGOs have been important, for example, in
shaping pharmaceutical policies and emphasising the
needs and rights of HIV-infected people.
The emergence of new global health policy actors – as a
result of new global legally independent public-private
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entities such as the Global Alliance for Vaccines and
Immunizations (GAVI), the Global Fund to Fight AIDS,
Malaria and Tuberculosis (GFATM) and the Global Alli-
ance for Improved Nutrition (GAIN) – to address selected
health issues at the turn of the century has further diversi-
fied the global health policy scene. Furthermore, new
challenges in health research have been defined under the
public-private partnership umbrella of the Global Forum
for Health Research.
Development aid to health has continued to grow sub-
stantially since 1992 despite the fall in total official devel-
opment assistance (ODA) since that time. The USA
provides about one third of the total bilateral aid to
health. Other bilateral donors are substantially smaller.
The multilateral agencies provide one third of the total
official development assistance to health and of that
assistance 80% comes from the International Develop-
ment Association (IDA) [12]. As a new funding source, the
Global Health programme of the Bill and Melinda Gates
Foundation (BMGF) has become not only significant in
size, but also in setting health policy. The funding from
the USA, IDA and the BMGF are of about the same order.
The US role in global health policy setting has increased
in the 1990s. [13] Traditionally the US AID emphases
have been on fostering goals such as privatization and
economic liberation, and on ties to US exports and tech-
nical assistance [14]. During the past decade, the USA has
been active in lifting global health issues in new forums,
such as the G8. The USA was also instrumental in the cre-
ation of the GFATM, towards which the EU, for instance,
was initially more critical. According to Kagan [15], the US
foreign policy is less inclined to act through international
institutions such as the UN and less inclined to work co-
operatively with other nations to pursue common goals,
while the European foreign policy emphasis is on multi-
lateralism over unilateralism.
Global health priorities
Global health priorities have in recent years been defined
through several processes and by several actors and at var-
ious forums. In 2000 and 2001, HIV/AIDS, tuberculosis
and malaria came to be discussed in a variety of forums at
the UN as well as outside the UN, and commitments to
address the three diseases were made, for example, by the
G8, the World Bank, the World Economic Forum and the
European Commission [16,17].
Millennium Development Goals (MDGs) [18] are a prod-
uct of consultations between international agencies, but
were also adopted by the United Nations (UN) General
Assembly in September 2001 as part of the road map for
implementing the substantially broader Millennium Dec-
laration, which it had adopted in September 2000 [19].
The MDGs have eight goals, three of which are health-
focussed, namely those on child mortality, maternal
health, and HIV/AIDS, malaria and other diseases.
The UN-led Millennium Project, directed by the econo-
mist Jeffrey Sachs, has the objective of ensuring that all
developing countries meet the MDGs. The whole UN sys-
tem has since been requested to adapt to addressing the
MDGs, and to report to the Secretary General on their
achievements in that direction. For health policies, this
has meant, for example, pressures from some of the mem-
ber states, such as the UK, for the WHO to refocus its work
on the MDGs, most notably to the goal concerning HIV/
AIDS, malaria and tuberculosis, while its wider mandate
as the normative health organisation that sets norms and
standards and promotes the building up a wider health
systems would not be so emphasised [20]. The MDGs
have become an important tool to steer both the UN sys-
tem towards a narrower agenda with more emphasis on
selected interventions and country presences, but more
recently increased attention has been placed on the need
for addressing development – including health policy
issues and systems – more comprehensively [21-23].
Largely the same priorities for health emerged from the
report of the Commission of Macroeconomics and Health
(CMH) in December 2001 [24], which concluded that
public health resources should be directed to the follow-
ing priorities: communicable diseases; malnutrition,
which exacerbates childhood infections; and maternal
and perinatal mortality.
Development aid for health is also largely steered towards
tackling communicable infectious [25]. USAID has
financed population programmes, including family plan-
ning, for three decades, while its emphasis on health
issues is more recent. In 2002, the USAID population,
health, and nutrition funding covered HIV/AIDS, family
planning/reproductive health, child survival/maternal
health, and infectious diseases [26]. The BMGF has pro-
vided strategic funding for the founding of new structures
for global health policy making – such as GAVI and GAIN
– and for the implementation of the recommendations
derived from the CMH. Its Global Health programme
focuses on infectious disease prevention, vaccine research
and development, and reproductive and child health,
with emphasis on the development and implementation
of technologies, though recurrent costs or chronic condi-
tions are not financed [28]. In GAVI, the substantial
BMGF funding is targeted at new vaccines. Efforts have
also been made to tackle health challenges through new
health technology research and development funding
under the Bill and Melinda Gates Foundation funded
Grand Challenges in Global Health initiative [29].Globalization and Health 2005, 1:6 http://www.globalizationandhealth.com/content/1/1/6
Page 3 of 5
(page number not for citation purposes)
According to global mortality and burden-of-disease cal-
culations, the above-set priorities indeed represent the
majority of deaths and ill-health in sub-Saharan Africa
[27], but do not represent the majority of ill-health in any
other region. They cover less that a third of the global ill-
health [24,27]. Today, non-communicable diseases are a
cause of the majority of ill-health in developing countries,
and their importance is increasing rapidly. They affect all
socioeconomic groups and in many cases the risks are big-
gest in the poorest sections of the populations [25].
Kickbusch [13] argues that global unilateralism has linked
the global health agenda to the US national interests, as
well as created a systematic effort to respond to the chal-
lenge of the present US administration to show effective-
ness. As a result, the four Es – economics, effectiveness,
efficiency, and evidence – are now the new battle cries for
the development community. Selected interventions to
eradicate infectious diseases fit well with these premises.
The lists of the current global health priorities can be seen
as reflecting health-related problems in the developing
countries that are perceived to threaten the vital interests
of industrialised countries. Linking national interests to
development aid is by no means new. In the 1970s, such
concerns were central in, for example, the argumentation
for population programme implementation [30,31]. Nev-
ertheless, it is noteworthy that since the mid-1990s the
arguments for a greater US engagement in global health
have been expressed increasingly in terms of national
interests or enlightened self-interest [13,16].
The joint strategic plan of the US Department of State and
the US Agency for International Development (USAID)
for the fiscal years 2004–2009 states that US foreign pol-
icy and development policy are fully aligned to advance
the National Security Strategy. The strategy sets out its
mission as being to create a more secure, democratic and
prosperous world for the benefit of the American people
and the international community. The purpose of the
Strategy is to help American business succeed in foreign
markets and help developing countries create conditions
for investment and trade [32].
Added emphasis on the trade and industrial policies has
been part of global development policies. The eighth
MDG is to develop global partnerships for development,
which includes developing an open trading and financial
system that is rule-based and non-discriminatory in co-
operation with both the pharmaceutical sector, for the
purpose of providing access to affordable medicines, and
in co-operation with the private sector in order to make
available the benefits of new technologies. The CMH also
argues for increased partnerships with business [24].
Approaches for improved global health
Health policy-making has become increasingly frag-
mented and verticalized, with the increasing emphases on
selected interventions, the increasing number of partner-
ships and especially because of the founding of new enti-
ties for various health issues. Little emphasis has been put
on comprehensive infrastructure building. These trends
are in contrast to the stated aims of integrating health pol-
icy making with the broader development agenda or with
comprehensive health sector planning.
An emphasis on innovations and innovative approaches
encourages the use of new technologies and the building
of new structures. Problems of unsustainability and ineq-
uity have arisen with the high levels of funding required,
an emphasis on fast results, and the construction of new
structures both at global and national levels [2,33-35]. In
the initial faces of GAVI serious concerns were raised that
those children that had been without basic vaccine cover-
age before GAVI funding would remain so and also be out
of the reach of the new vaccines [33,36]. The GAVI
emphasis on new and more expensive vaccines have
raised the costs of the immunizations programmes at
country level making the future financing of the pro-
grammes highly vulnerable [37].
National priorities often differ from the global priorities,
and the thinking around global public goods recognizes
this as a starting point. Yamey [34] has argued that the
increased emphasis on global programmes and global pri-
ority setting is problematic from the point of view of
national sovereignty and empowerment. He furthermore
states that partnerships rarely synchronise their activities
with emerging processes within countries aimed at devel-
oping their national health systems. This observation has
also been made in relation to GAVI country level action
[38].
Partnerships are commonly defined as voluntary and col-
laborative relationships between state and non-state par-
ticipants who agree to work together to achieve a common
purpose or undertake a specific task, and to share risks,
responsibilities, resources, competencies and benefits
[39]. According to Richter [7] one of the most substantive
losses resulting from the shift towards the partnership par-
adigm is the loss of distinction between different actors in
the global health arena. UN agencies, governments, tran-
snational corporations, their business associations and
public interest NGOs are all called 'partner'. The realisa-
tion that these actors have different and possibly conflict-
ing mandates, goals and roles has been lost.
The inclusion of business as an integral part of public pol-
icy making may weaken the vital role of the public sector
in norm- and standard setting and monitoring, as theGlobalization and Health 2005, 1:6 http://www.globalizationandhealth.com/content/1/1/6
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public sector has been made an equal partner with busi-
ness, sharing a common purpose and tasks. The WHO col-
laboration with business has caused harm to the
credibility of the WHO's normative functions [7,40-43].
The legally independent global PPPs are structured so that
public bodies with normative functions hold seats in the
policy-making bodies together with business representa-
tives both at global and national levels. This 'forced mar-
riage' within the legally independent PPPs may harm not
only the credibility of the normative functions of the reg-
ulators, but also the normative functions as such. In GAIN
and in the UNFPA private sector initiative, the normative
bodies are directly requested for 'supportive environ-
ments' as regards regulation, taxes and tariffs [6].
GAVI, GFATM and GAIN deal with essential health issues.
Selected UN agencies (in the case of GAIN only one UN or
other multilateral agency) that have mandates to deal
with these health matters are invited to join their boards
either as voting (GAVI and GAIN) or non-voting
(GFATM) members, while industry and other private sec-
tor actors are included as full members at all levels of their
structures [2,6]. The marginalisation of the UN in the
structures of the legally independent global PPPs did not
happen accidentally. The cautious approach of the WHO
to integrating private industry into its activities has been
reported as one of the main reasons for GAVI's construc-
tion as an independent legal body. Problems were
encountered, for example, when issues of intellectual
property rights and profits arose [44]. According to Phil-
lips [45], the USA opposed the running of GFATM by
either the UN or the World Bank. The US also demanded
that the fund set up a world-wide aid-delivery system
instead of relying on established agencies, such as the UN
and the World Bank.
According to Stansfield et al. [46] many public sector lead-
ers have raised the concern that in its eagerness to address
market failures and pursue international public goods,
PPPs are often structured so that the public sector absorbs
the lion's share of the risks and costs, while the private sec-
tor absorbs a disproportionate share of the profit. On a
more general note, a report by the International Monetary
Fund has raised concerns over the inadequate risk-sharing
in public-private partnerships [47]. This tendency can be
demonstrated, for example, by the UNFPA private-sector
initiative, which aimed at increasing access to reproduc-
tive health commodities. According to the initiative, gov-
ernments were to give preferential tax and duty conditions
and ease manufacturing and import regulations, as well as
undertake and support market-related research, the
donors were to provide support for marketing, advertising
and marketing research, while the selected transnational
contraceptive producers were requested to sell their prod-
ucts at affordable prices, and handle distribution and
implement market-building activities. The initiative also
suggested that the governments and the donors could
improve the policy environment for private sector invest-
ment and security, and facilitate the building of an exten-
sive distribution system so as to reduce the costs for the
private sector. Transnational contraceptive producers were
instrumental in the selection of the target developing
countries, many of which had significant domestic contra-
ceptive production [48].
Conclusion
While globalisation increases the risk that infectious dis-
eases travel from South to North, it has also increased the
risk that major risk factors for non-communicable dis-
eases travel from North to South. Currently, global public
health policies are concentrated on selected conditions
around infectious diseases and on the technological solu-
tions for them. Addressing infectious diseases in the South
is important. However, other health matters are increas-
ingly being left for private actors to deal with. Addressing
the most important risk factors of non-communicable dis-
eases, namely tobacco, alcohol and unhealthy foods,
would benefit from normative actions, including restric-
tions on trade and marketing [25]. Simultaneously, global
health policy making is increasingly aligned with indus-
trial and trade policies, and is being done hand in hand
with business, thus weakening the firewalls necessary for
effective regulation and normative actions both at global
and national levels.
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